Surrogate endpoints in Parkinson's disease research

被引：7
作者：
Kevin M. Biglan
Robert G. Holloway
机构：
[1] Department of Neurology, University of Rochester, Rochester, NY 14620
来源：
Current Neurology and Neuroscience Reports | 2003年 / 3卷 / 4期
关键词：
Levodopa; Single Photon Emission Compute Tomography; Pramipexole; Surrogate Endpoint; Ropinirole;
D O I：
10.1007/s11910-003-0008-y
中图分类号：
学科分类号：
摘要：
Biomarkers are important tools in understanding the underlying mechanisms of causation, progression, and treatment effects in Parkinson's disease (PD). In addition, these biomarkers may be utilized as surrogate endpoints that, when used appropriately, can lead to important advances in therapeutics in a timely and cost-effective manner. This paper outlines the definition, role, validity process, and risks associated with surrogate endpoints. The use of biomarkers in recent PD clinical trials is discussed and potential shortcomings and unanswered questions related to interpreting these outcomes are reviewed. Finally, the significant challenges that lie ahead for validating and interpreting surrogate endpoints in PD are addressed. Copyright © 2003 by Current Science Inc.
引用
收藏
页码：314 / 320
页数：6
相关论文
共 51 条
[1]  
Temple R.J., A regulatory authority's opinion about surrogate endpoints, Clinical Measurement in Drug Evaluation, (1995)
[2]  
Schatzkin A., Understanding clinical trials: Intermediate markers as surrogate endpoints in cancer research, Hematol. Oncol. Clin. North Am., 14, pp. 1-15, (2000)
[3]  
De Gruttola V., Fleming T., Lin D.Y., Coombs R., Perspective: Validating surrogate markers-are we being naive?, J. Infect. Dis., 175, pp. 237-246, (1997)
[4]  
Wittes J., Lakatos E., Probstfield J., Surrogate endpoints in clinical trials: Cardiovascular diseases, Stat. Med., 8, pp. 415-425, (1989)
[5]  
Johnston K.C., What are surrogate outcome measures and why do they fail in clinical research?, Neuroepidemiology, 18, pp. 167-173, (2000)
[6]  
Hillis A., Surrogate endpoints in clinical trials: Ophthalmologic disorders, Stat. Med., 8, pp. 427-430, (1989)
[7]  
Miller D.H., Multiple sclerosis: Use of MRI in evaluating new therapies, Semin. Neurol., 18, pp. 317-325, (1998)
[8]  
Brooks D.J., Monitoring neuroprotection and restorative therapies in Parkinson's disease with PET, J. Neural. Transm. Suppl., 60, pp. 125-137, (2000)
[9]  
Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction, N. Engl. J. Med., 321, pp. 406-412, (1989)
[10]  
Hine L.K., Laird N., Hewitt P., Chalmers T.C., Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction, Arch. Intern. Med., 149, pp. 2694-2698, (1989)
123456